Where can I buy Sotoracib (AMG510)?

Sotorasib (AMG510, Sotorasib) is a targeted therapeutic drug targeting the KRAS G12C mutated oncoprotein. It is mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations who have received at least one systemic therapy in the past. The drug was developed by Amgen and has attracted widespread attention around the world because it is the world's first successfully developed KRAS G12C inhibitor after more than 40 years of research on KRAS mutated cancer proteins.

The KRAS gene is an important oncogene in human cells and is mutated in a variety of malignant tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer. Sotorasiib works by inhibiting the activation of the mutated KRAS gene, locking the KRAS protein in an inactive state, thereby preventing it from sending signals that drive uncontrolled cell growth. This targeted therapy is highly specific and can act on cancer cells with KRAS G12C mutations, while having no effect on unmutated KRAS proteins. Sotorasiib blocks the proliferation and survival of malignant tumor cells by inhibiting the activity of this specific mutant KRAS protein.

At present, sotorasibu has not been approved for marketing in China, so it cannot be purchased through formal domestic channels. Since sotoracib is a prescription drug, patients must use it under the guidance of a doctor and strictly abide by the doctor's instructions and the medication instructions on the drug insert. If patients really need to use the drug, they need to consider overseas import or other methods to obtain it through legal means. At the same time, due to the high price of this drug, patients need to fully understand its financial burden and make reasonable decisions before using it.